Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
"The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people."
Worsening patient outcomes because of care delays call for accelerated AI adoption
About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days.
Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times.
AI has the potential to transform care delivery and significantly improve patient outcomes across APAC.
Workforce challenge and data burdens call for AI relief
Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago.
These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden. [1]
About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented:
Addressing AI concerns from HCPs and patients crucial for widespread adoption
A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes.
Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%).
Trust key to transforming healthcare in APAC
For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area.
For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%).
Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies.
"It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems."
For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips.
About the Future Health Index 2025
The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit www.philips.com/futurehealthindex-2025.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
19 hours ago
- Korea Herald
AMSC Malaysia 2025 Set to Spotlight World-Class Expertise and Innovation in Aesthetic Medicine and Surgery
KUALA LUMPUR, Malaysia, July 24, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its fourth edition from August 6-7, 2025, with an expanded focus on global participation and advanced education. Held at the Kuala Lumpur Convention Centre (KLCC), AMSC 2025 will feature over 160 world-class speakers, 200 international brands, and 20 supporting partners, including 13 medical societies and 7 industry collaborators. More than 1,600 delegates from around the world are expected, with highlights including clinical innovation updates, live demonstrations, and expert insights from speakers representing over 30 countries. "AMSC Malaysia 2025 represents a global crossroads for aesthetic medicine, where regional insights meet international expertise. This year, we are not just sharing techniques, we are also building a collaborative future for the field by fostering dialogue, discovery, and innovation across borders," said Dr Tingsong Lim, President of the Malaysian Society of Aesthetic Medicine (MSAM) and Scientific Director of AMSC. Elevating Aesthetic and Regenerative Care for Diverse Needs AMSC Malaysia 2025 will explore a wide range of cutting-edge topics in aesthetic and regenerative medicine. These include Periorbital Rejuvenation, focusing on advanced techniques using fillers, threads, and devices to treat tear troughs and under-eye ageing; Melasma Management, with evidence-based protocols combining lasers, topicals, and regenerative treatments tailored for Asian skin; Facelift Techniques, covering both surgical and non-invasive approaches such as thread lifts, energy-based tightening, and facial sculpting; Longevity Medicine, exploring anti-ageing strategies that utilise semaglutide, hormones, peptides, and polydeoxyribonucleotides (PDRN); Regenerative Aesthetics, highlighting the use of exosomes, stem cells, and PRP to restore skin quality and stimulate collagen; Scar Treatment, featuring multi-modal solutions using lasers, injectables, and biostimulators for acne scars and post-surgical healing; and more. Through these sessions, delegates will gain in-depth knowledge of current clinical trends, master advanced injection and device-based techniques, and learn how to apply combination approaches for improved patient outcomes. The conference provides ample opportunities for attendees to explore innovations in regenerative medicine, deepen their understanding of tailored treatments for diverse skin types and enhance their ability to meet the growing demands of specialised patient segments, including male aesthetics and ageing populations. This year's AMSC welcomes a distinguished line-up of global experts who are redefining the standards of aesthetic and regenerative medicine: The PINOKIO Surgical Zone Returns with Expanded Hands-On Training Returning for its eighth edition in Malaysia, the PINOKIO Surgical Zone at AMSC 2025 brings back Korea's leading surgical organisation for an expanded three-day programme from 6 to 8 August 2025. In a groundbreaking collaboration, AMSC partners with the Plastic Innovative Nasal Ormaxillofacial Korean International Organisation (PINOKIO) to deliver an immersive and focused surgical education experience tailored for professionals seeking to refine their techniques and deepen their anatomical understanding. The agenda includes Day 1: Nose Surgery Focus, Day 2: Face and Chest Lift Techniques, and Day 3: Hands-on Cadaver Masterclass on Rhinoplasty and Surgical Facelift. Delegates will benefit from expert-led lectures, live cadaver dissections, and practical demonstrations guided by some of Asia's most respected surgeons. Additionally, the zone features a curated exhibition showcasing the latest tools and innovations in facial, nasal, and chest aesthetic surgery. Additionally, the exhibition hall will feature leading global brands such as Merz Aesthetics, Juvederm, Skinvive, Neauvia, Oligio, Gouri, Karisma, Multifrax, Sinclair, and Plinest, offering delegates hands-on access to the latest innovations in injectables, energy-based devices, and regenerative solutions.
Korea Herald
2 days ago
- Korea Herald
Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025
SEOUL, South Korea, July 23, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world's largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm. Automating every step of PCR Testing for enhanced efficiency and accuracy CURECA™ is the world's first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results. A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling. The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments. In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory. STAogra ™ – Real-Time Global Data Integration Empowering Personalized Care Also unveiled at ADLM 2025, STAgora™ is Seegene's statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support. With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making. Expanding Global Collaboration via Technology Sharing and Strategic Partnerships Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships. Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe's leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA. "CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we've built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem." Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene. Disclaimer The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.
Korea Herald
2 days ago
- Korea Herald
Global Dental Leaders to Convene in Shanghai for FDI World Dental Congress 2025
SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the oral health profession, will take place in Shanghai, China, from September 9–12, 2025, co-hosted by Chinese Stomatological Association and Reed Sinopharm Exhibitions. Organized annually in different countries, the WDC highlights the importance of oral health in securing overall health and well-being and serves as a driving force for international collaboration in dentistry. In recent years, visa-free policies have made China an increasingly popular destination for global travelers. This enhanced accessibility, coupled with Shanghai's global appeal, and FDI's established reputation as the leading global dental event, has already attracted over 10,000 congress delegates for the 2025 edition, with expectations of more than 35,000 professional attendees and visitors from 134 countries and regions. Attendees can look forward to a robust scientific program packed with insights from over 300 world-class speakers and interactive forums on key dental topics. Meanwhile, the FDI WDC 2025 Exhibition is set to be the largest in FDI history, featuring 700 selected exhibitors across 60,000 square meters. Leading global brands such as Haleon, Listerine, LION, and Colgate, along with hundreds of Chinese manufacturers and technology providers, will showcase the most advanced dental equipment and solutions. The exhibition will also spotlight achievements from hospitals and universities, innovations in AI-powered diagnostics, digital dentistry, and 3D printing, providing state-of-the-art solutions to participants. Additionally, the Congress promises exceptional networking opportunities through guided tours designed to connect researchers, clinicians, industry experts, and distributors, fostering partnerships that can advance oral health globally. A Social Program to Remember The social program accompanying WDC25 will provide attendees with a unique cultural experience. Highlights include the Opening Ceremony on September 9, and the Gala Dinner on September 10 invites guests to immerse themselves in Chinese heritage through live performances, regional cuisine, and an evening celebrating cultural elegance. Shanghai Night set for September 11, will be held along the iconic Bund, offering a memorable evening of live music, handcrafted cocktails, and stunning views of Shanghai's dynamic skyline. These events perfectly capture the city's vibrant "East-meets-West" charm and cultural essence. China's Emergence as a Dental Destination While the Congress takes center stage, China's rise as a key market for dentistry cannot be overlooked. Since 2006, China's dental sector has experienced unprecedented growth, outpacing most global markets. The sector's technological transformation has been equally impressive. Chinese dental practices have rapidly adopted cutting-edge solutions including fully digital workflows, fundamentally enhancing treatment accuracy, efficiency, and patient comfort - setting new standards for dental care delivery. Driving Global Oral Health Forward The FDI World Dental Congress continues to set the benchmark for advancing oral health on the global stage. By uniting leaders from across the dental profession, WDC25 will showcase dentistry's most pressing innovations, address key health challenges, and foster greater collaboration to improve oral care around the world.
